Viridian Therapeutics
VRDN
225 hedge funds and large institutions have $2.21B invested in Viridian Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 80 increasing their positions, 67 reducing their positions, and 50 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 67
2% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 50
2% less funds holding
Funds holding: 229 → 225 (-4)
3.02% less ownership
Funds ownership: 112.97% → 109.95% (-3%)
34% less capital invested
Capital invested by funds: $3.36B → $2.21B (-$1.14B)
41% less call options, than puts
Call options by funds: $6.26M | Put options by funds: $10.7M
54% less funds holding in top 10
Funds holding in top 10: 13 → 6 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$70.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$53.8M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$50.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$48.7M |
| 5 |
BlackRock
New York
|
+$41.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$55.6M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$33.6M |
| 3 |
Jennison Associates
New York
|
-$33.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$32.9M |
| 5 |
EP
Eversept Partners
New York
|
-$31.7M |
VRDN Hedge Fund Activity: Q1 2026 in Review
225 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2026, worth a combined $2.21B — down 34% from $3.36B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of VRDN and 49 opened new positions — a net loss of 1 holder — while 67 trimmed existing stakes and 80 added.
The largest buyer was Bellevue Group, adding an estimated $70.3M. The largest seller was Perceptive Advisors, cutting an estimated $55.6M.
- 225 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2026, down from 229 in Q4 2025.
- Funds reported $2.21B of Viridian Therapeutics stock for Q1 2026, down 34% quarter-over-quarter.
- 49 funds opened new Viridian Therapeutics positions in Q1 2026 and 50 closed out, a net change of -1 holder.
- The largest Viridian Therapeutics buyer in Q1 2026 was Bellevue Group, an estimated $70.3M added.
- The largest Viridian Therapeutics seller in Q1 2026 was Perceptive Advisors, an estimated $55.6M sold.
Based on aggregated 13F filings for Q1 2026.